Latest Press Releases Nov 24 2023 Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations Read More Nov 23 2023 European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Read More Nov 16 2023 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Read More Nov 06 2023 Vertex Reports Third Quarter 2023 Financial Results Read More Nov 02 2023 Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition Read More Nov 02 2023 Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference Read More Load More Recent Media Library Items View All Date - Any -202120222023 Tags Download LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Sickle Cell Disease and Beta Thalassemia Patient Perspectives Download 914 KB Date - Any -202120222023 Tags Download LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Jonathan Biller Executive Vice President and Chief Legal Officer Download Date - Any -202120222023 Tags Download LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Image Folder Patient One Pager Photos for Media Use DOWNLOAD 16 MB Date - Any -202120222023 Tags Download LibraryEmployee working at Vertex Manufacturing Center (VMC), Boston, MAEmployee working at Vertex Manufacturing Center, Boston, MAEntrance of The Jeffrey Leiden Center for Cell and Genetic Therapies, Boston, MAExterior of Vertex headquarters in Boston, MAExterior of Vertex headquarters in Paddington, UKExterior of Vertex research site in Oxford, UKExterior of Vertex research site in San Diego, CAImagesInterior of Vertex headquarters in Boston, MALiving with beta thalassemiaLiving with sickle cell diseaseLiving with transfusion-dependent beta thalassemiaLiving with transfusion-dependent thalassemiaMother to three daughters living with sickle cell diseaseResearcher in Vertex Oxford labResearcher in Vertex San Diego labResearchers in Vertex Boston labResearchers in Vertex Oxford labResearchers in Vertex San Diego lab Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Nov 24 2023 Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations Read More
Nov 23 2023 European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Read More
Nov 16 2023 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Read More
Nov 02 2023 Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition Read More
Nov 02 2023 Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference Read More
